The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
Compounded semaglutide medications are custom-made by compounding pharmacies, containing the active ingredient in Ozempic and Wegovy. However, they are not FDA-approved and carry potential risks. This article explains what you need to know about these alternatives.
WeightWatchers is undergoing a brand refresh to better integrate GLP-1 medications into its offerings. This shift comes after the company's bankruptcy filing, which cited the rapidly evolving weight management landscape. The rebrand includes new programs and features designed to support members using these medications.
Shed has announced the release of three new wellness solutions: microdose GLP-1, NAD+, and Glutathione. These programs aim to enhance energy, focus, and promote healthy aging through practical and sustainable methods.
The GLP-1 agonist market is undergoing significant expansion, fundamentally changing how Type 2 Diabetes and obesity are addressed globally. This drug class, initially for glycemic control, has become a key therapeutic option for weight management and cardiovascular risk reduction. The rising popularity of these drugs has sparked a pharmaceutical boom, with focus shifting to advanced agonists offering even greater metabolic advantages.
One woman details her shift in Christmas spending priorities to fund weight-loss injections. Discover how she's saving money on gifts, meals, and outings to maintain her health goals.
Obesity in pets is a growing concern, linked to various health issues. As weight-loss drugs gain popularity for humans, the possibility of using similar medications for pets is being explored. However, experts emphasize the importance of addressing the root causes of pet obesity through diet and exercise.
Eli Lilly is currently thriving, fueled by the success of its GLP-1 drugs. However, factors such as market competition and the eventual expiration of patent protections pose potential challenges to its long-term growth.
The global GLP-1 agonists market is anticipated to reach over USD 260.1 billion by 2034, demonstrating a CAGR of 19.9% during the forecast period. This growth is driven by innovations in diabetes, obesity, and cardiovascular disease treatments, though high costs and administration challenges remain.
Anupam Mittal raised concerns about the potential overuse of drugs like Ozempic for weight loss. He also highlighted the upcoming expiration of key GLP-1 drug patents, possibly leading to market changes.
